242 related articles for article (PubMed ID: 27677932)
1. Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.
Török N; Majláth Z; Szalárdy L; Vécsei L
Expert Opin Investig Drugs; 2016 Nov; 25(11):1281-1294. PubMed ID: 27677932
[TBL] [Abstract][Full Text] [Related]
2. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
Lawand NB; Saadé NE; El-Agnaf OM; Safieh-Garabedian B
Expert Opin Ther Targets; 2015; 19(10):1351-60. PubMed ID: 26135549
[TBL] [Abstract][Full Text] [Related]
3. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
Chaari A; Hoarau-Véchot J; Ladjimi M
Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological therapy of Parkinson's disease: current options and new avenues.
Simola N; Pinna A; Fenu S
Recent Pat CNS Drug Discov; 2010 Nov; 5(3):221-38. PubMed ID: 20726838
[TBL] [Abstract][Full Text] [Related]
5. Activating Autophagy as a Therapeutic Strategy for Parkinson's Disease.
Fowler AJ; Moussa CE
CNS Drugs; 2018 Jan; 32(1):1-11. PubMed ID: 29492779
[TBL] [Abstract][Full Text] [Related]
6. New therapeutic approaches to target alpha-synuclein in Parkinson's disease: The role of immunotherapy.
Fernández-Valle T; Gabilondo I; Gómez-Esteban JC
Int Rev Neurobiol; 2019; 146():281-295. PubMed ID: 31349931
[TBL] [Abstract][Full Text] [Related]
7. New treatments for the motor symptoms of Parkinson's disease.
Vijverman AC; Fox SH
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835
[TBL] [Abstract][Full Text] [Related]
8. Treatments and compositions targeting α-synuclein: a patent review (2010-2016).
Jęśko H; Lenkiewicz AM; Adamczyk A
Expert Opin Ther Pat; 2017 Apr; 27(4):427-438. PubMed ID: 27841042
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
George S; Brundin P
J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
[TBL] [Abstract][Full Text] [Related]
10. Alpha-synuclein and iron: two keys unlocking Parkinson's disease.
Lingor P; Carboni E; Koch JC
J Neural Transm (Vienna); 2017 Aug; 124(8):973-981. PubMed ID: 28168622
[TBL] [Abstract][Full Text] [Related]
11. Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy.
Ganguly U; Chakrabarti SS; Kaur U; Mukherjee A; Chakrabarti S
Curr Neuropharmacol; 2018; 16(7):1086-1097. PubMed ID: 29189163
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders.
Amer DA; Irvine GB; El-Agnaf OM
Exp Brain Res; 2006 Aug; 173(2):223-33. PubMed ID: 16733698
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase 6 regulates cytotoxic α-synuclein accumulation through induction of the heat shock response.
Du Y; Wang F; Zou J; Le W; Dong Q; Wang Z; Shen F; Yu L; Li Y
Neurobiol Aging; 2014 Oct; 35(10):2316-28. PubMed ID: 24866403
[TBL] [Abstract][Full Text] [Related]
14. α-Synuclein ubiquitination and novel therapeutic targets for Parkinson's disease.
Rott R; Szargel R; Shani V; Bisharat S; Engelender S
CNS Neurol Disord Drug Targets; 2014; 13(4):630-7. PubMed ID: 24168368
[TBL] [Abstract][Full Text] [Related]
15. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
[TBL] [Abstract][Full Text] [Related]
16. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
[TBL] [Abstract][Full Text] [Related]
17. Pathological and clinical aspects of alpha/beta synuclein in Parkinson's disease and related disorders.
Tolmasov M; Djaldetti R; Lev N; Gilgun-Sherki Y
Expert Rev Neurother; 2016 May; 16(5):505-13. PubMed ID: 26959397
[TBL] [Abstract][Full Text] [Related]
18. Preventing α-synuclein aggregation: the role of the small heat-shock molecular chaperone proteins.
Cox D; Carver JA; Ecroyd H
Biochim Biophys Acta; 2014 Sep; 1842(9):1830-43. PubMed ID: 24973551
[TBL] [Abstract][Full Text] [Related]
19. A pragmatic approach to biochemical systems theory applied to an alpha-synuclein-based model of Parkinson's disease.
Sass MB; Lorenz AN; Green RL; Coleman RA
J Neurosci Methods; 2009 Apr; 178(2):366-77. PubMed ID: 19136028
[TBL] [Abstract][Full Text] [Related]
20. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models.
Sato H; Kato T; Arawaka S
Rev Neurosci; 2013; 24(2):115-23. PubMed ID: 23314528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
